Pacific Biosc Stock Price, News & Analysis

PacBio (NASDAQ: PACB), a top developer of high-quality sequencing solutions, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 5, at 1:05 p.m. Eastern Time.

The event will be live-streamed on PacBio's investors page at investor.pacificbiosciences.com. For those unable to attend live, a replay will be available for at least 30 days following the event. This presentation offers investors and interested parties an opportunity to gain insights into PacBio's latest developments and future prospects in the sequencing technology sector.

PacBio (NASDAQ: PACB) reported Q2 2024 financial results with revenue of $36.0 million, down from $47.6 million in Q2 2023. The company faced headwinds in the capital equipment market, particularly in Europe and Asia. Key highlights include:

- Instrument revenue: $14.7 million (24 Revio™ systems sold)
- Consumables revenue: $17.0 million
- Service and other revenue: $4.3 million
- Net loss: $173.3 million ($0.64 per share)
- Non-GAAP net loss: $55.2 million ($0.20 per share)

Despite challenges, PacBio sees positive developments in population genomics programs and increasing adoption of Revio in clinical research. The company remains on track to reduce annual run rate expenses by over $75 million while maintaining key product development programs.

PacBio (NASDAQ: PACB) has partnered with Singapore's National Precision Medicine (NPM) programme to advance HiFi Sequencing in Southeast Asia. Precision Health Research, Singapore (PRECISE) has selected PacBio's Revio HiFi sequencing system for its Long-Read Sequencing Flagship Project, aiming to create the largest long-read sequencing dataset in the region. This collaboration will provide insights into genetic diversity, disease mechanisms, and clinical diagnoses within Singapore's multi-ethnic population.

The project includes:

• 60x HiFi depth for Pan-Asian reference genomes
• 20x HiFi depth for multi-omics analysis
• 30x HiFi depth for cancer and rare disease cases

PacBio will establish advanced sequencing infrastructure in Singapore, with Macrogen Asia Pacific Pte as the appointed service provider. The partnership leverages AWS cloud storage for secure data processing and access.

PacBio (NASDAQ: PACB) announced that Novogene is using its Revio long-read sequencing system to expand capabilities at its new lab in Munich, Germany. The Revio system's increased accuracy and throughput are designed to enable Novogene's customers to scale genomic research across rare diseases, cancer, microbes, and agriculture cost-effectively.

Novogene anticipates high demand for Revio from customers in rare disease and cancer research, as well as in microbial and agrigenomics fields. The system's ability to uncover complex repetitive regions, structural variants, and novel isoforms makes it valuable for advanced genomic studies. Novogene plans to integrate more automation into Revio's workflows to increase efficiency and accessibility for a wider range of customers.

PacBio (NASDAQ: PACB) has announced its upcoming second quarter 2024 financial results conference call, scheduled for Wednesday, August 7, 2024, at 4:30 pm Eastern Time (1:30 pm Pacific Time). Investors and interested parties can access the webcast through PacBio's investor relations website. For those preferring a dial-in option, toll-free and international numbers are provided. Participants are advised to join the call ten minutes before the start time. This event will provide insights into PacBio's financial performance and potentially discuss key developments in the genomics and life sciences sector.

PacBio (NASDAQ: PACB) and the international Consortium for Long-Read Sequencing (CoLoRS) have launched the first publicly available HiFi long-read variant frequency database. This database, globally representative and free, addresses critical gaps in rare disease research by providing access to genetic variants undetectable through short-read sequencing.

Notably, long-read sequencing detects 15,000 more structural variants and 300,000 more small variants than short-read methods. The CoLoRS database, incorporating data from nearly 1,000 long-read genomes, aids in understanding complex genetic variations and their disease implications. This initiative supports significant advancements in oncology, rare diseases, and genetic disorders research.

Ambry Genetics and PacBio (PACB) have announced a collaboration with the University of California, Irvine (UCI) and the GREGoR Consortium to support the Pediatric Mendelian Genomics Research Center program. This initiative aims to sequence up to 7,000 human genomes over three years, focusing on rare diseases. The research will leverage long-read sequencing technology to uncover new genetic variants and enhance understanding of disease biology. The collaborative effort is expected to provide insights that could revolutionize diagnostic capabilities for rare diseases.

PacBio announced its financial results for the first quarter of 2024, reporting a revenue of $38.8 million, a 16% increase in gross profit compared to the prior year, and a net loss of $78.2 million. The company highlighted new product launches and cost-cutting measures to improve revenue and reduce expenses. Cash, cash equivalents, and investments totaled $561.9 million at the end of March 2024.